Terrestrial Bio Secures $50M, Pioneers Future of Drug Delivery
March 29, 2026, 3:37 pm
Terrestrial Bio secured $50M in Series C funding, rebranding from Vaxess Technologies. The biotech leader pioneers a microarray patch (MAP) platform. This innovative technology revolutionizes drug delivery. It enables self-administration of therapeutics, initially targeting GLP-1 treatments. The platform is needle-free and temperature-stable. It significantly enhances patient convenience and adherence. Funding fuels a new Boston manufacturing facility. This expansion scales automated production for late-stage clinical trials and market entry. Terrestrial Bio aims to transform global healthcare access and patient experience, driving a new era in medicine.
Terrestrial Bio is reshaping medicine. The biotech company recently closed a $50 million Series C funding round. This substantial investment marks a pivotal moment. The company also announced a strategic rebrand from Vaxess Technologies. The fresh capital injection will propel Terrestrial Bio's innovative drug delivery platform. It targets a future of accessible, patient-friendly therapeutics.
RA Capital led the funding round. Other notable participants included Engine Ventures, GHIC, and SiteGround. This backing signals strong investor confidence. It validates the potential of Terrestrial Bio's proprietary technology. The rebrand reflects a sharpened focus. The company now prioritizes therapeutic delivery and enhanced patient access. This shift is crucial for modern healthcare.
Terrestrial Bio develops a unique microarray patch (MAP) platform. This technology promises to transform how drugs are administered. The patch resembles a small adhesive bandage. A preloaded applicator applies it to the skin. It delivers microscopic bioactive tips. These tips dissolve rapidly. They release therapeutic compounds directly into the body.
The MAP platform boasts significant advantages. It allows for self-administration. Patients can apply the patch at home. This eliminates the need for professional healthcare visits for injections. The technology also removes the necessity for medical sharps. This addresses widespread needle phobia. It improves patient comfort and safety.
Crucially, the MAP platform is temperature-stable. This feature removes the "cold chain" requirement. Many traditional injectable drugs need constant refrigeration. This creates logistical hurdles. It limits access in remote areas. Terrestrial Bio's solution offers unparalleled convenience. It enables therapy use anywhere, anytime.
Patient experience drives innovation. The company highlights this commitment. Recent studies support the patch's superiority. A GLP-1 human factors study showed clear preference. Nearly all participants favored the patch applicator. They chose it over conventional injection devices. This suggests improved adherence. Better adherence leads to better health outcomes.
Terrestrial Bio's initial focus targets GLP-1 treatments. GLP-1 agonists are powerful medications. They treat diabetes and obesity. Current GLP-1 therapies often require injections. These can be daily or weekly. The MAP platform provides a non-invasive alternative. This could be a game-changer. It unlocks broader adoption for these vital drugs.
The $50 million funding enables critical expansion. Terrestrial Bio has secured a lease in Boston. This will be its new headquarters. It will also house a state-of-the-art manufacturing facility. The site spans over 40,000 square feet. It is located in Boston’s Allston Labworks.
Construction for the facility begins in 2026. This new site will be highly advanced. It incorporates cutting-edge automation. Robotics will streamline production processes. Computer vision systems will ensure quality control. These features support scaled production. They are essential for late-stage clinical development. They prepare for early commercial entry.
The company's vision extends beyond GLP-1s. Its platform demonstrates broad applicability. It has shown strong clinical and in vivo proof of concept. This applies across multiple molecules. The MAP technology holds promise for various therapeutic areas. It could revolutionize delivery for vaccines. It may benefit biologics and other complex drugs.
Terrestrial Bio is not just developing a product. It is building a new paradigm for drug delivery. The company aims to dismantle barriers. These barriers often impede patient access. They complicate treatment regimens. Its technology makes medicine more personal. It makes it more manageable for individuals.
The rebrand to Terrestrial Bio reflects this broader ambition. "Terrestrial" signifies a grounded approach. It points to a surface-based technology. It also implies a global reach. The company seeks to impact patients worldwide. It connects innovative science with human needs.
Healthcare continues to evolve. Consumerization plays a growing role. Patients demand convenience. They expect ease of use. Terrestrial Bio addresses these demands directly. It offers a path to improved quality of life. It makes managing chronic conditions simpler.
This strategic investment positions Terrestrial Bio strongly. It enters a crucial phase of growth. The new manufacturing capabilities are vital. They ensure robust supply chains. They support global distribution plans. The company is set to advance next-generation therapies. It promises improved patient accessibility and unparalleled ease of use. This is the future of medicine, delivered directly to the skin.
Terrestrial Bio is reshaping medicine. The biotech company recently closed a $50 million Series C funding round. This substantial investment marks a pivotal moment. The company also announced a strategic rebrand from Vaxess Technologies. The fresh capital injection will propel Terrestrial Bio's innovative drug delivery platform. It targets a future of accessible, patient-friendly therapeutics.
RA Capital led the funding round. Other notable participants included Engine Ventures, GHIC, and SiteGround. This backing signals strong investor confidence. It validates the potential of Terrestrial Bio's proprietary technology. The rebrand reflects a sharpened focus. The company now prioritizes therapeutic delivery and enhanced patient access. This shift is crucial for modern healthcare.
Terrestrial Bio develops a unique microarray patch (MAP) platform. This technology promises to transform how drugs are administered. The patch resembles a small adhesive bandage. A preloaded applicator applies it to the skin. It delivers microscopic bioactive tips. These tips dissolve rapidly. They release therapeutic compounds directly into the body.
The MAP platform boasts significant advantages. It allows for self-administration. Patients can apply the patch at home. This eliminates the need for professional healthcare visits for injections. The technology also removes the necessity for medical sharps. This addresses widespread needle phobia. It improves patient comfort and safety.
Crucially, the MAP platform is temperature-stable. This feature removes the "cold chain" requirement. Many traditional injectable drugs need constant refrigeration. This creates logistical hurdles. It limits access in remote areas. Terrestrial Bio's solution offers unparalleled convenience. It enables therapy use anywhere, anytime.
Patient experience drives innovation. The company highlights this commitment. Recent studies support the patch's superiority. A GLP-1 human factors study showed clear preference. Nearly all participants favored the patch applicator. They chose it over conventional injection devices. This suggests improved adherence. Better adherence leads to better health outcomes.
Terrestrial Bio's initial focus targets GLP-1 treatments. GLP-1 agonists are powerful medications. They treat diabetes and obesity. Current GLP-1 therapies often require injections. These can be daily or weekly. The MAP platform provides a non-invasive alternative. This could be a game-changer. It unlocks broader adoption for these vital drugs.
The $50 million funding enables critical expansion. Terrestrial Bio has secured a lease in Boston. This will be its new headquarters. It will also house a state-of-the-art manufacturing facility. The site spans over 40,000 square feet. It is located in Boston’s Allston Labworks.
Construction for the facility begins in 2026. This new site will be highly advanced. It incorporates cutting-edge automation. Robotics will streamline production processes. Computer vision systems will ensure quality control. These features support scaled production. They are essential for late-stage clinical development. They prepare for early commercial entry.
The company's vision extends beyond GLP-1s. Its platform demonstrates broad applicability. It has shown strong clinical and in vivo proof of concept. This applies across multiple molecules. The MAP technology holds promise for various therapeutic areas. It could revolutionize delivery for vaccines. It may benefit biologics and other complex drugs.
Terrestrial Bio is not just developing a product. It is building a new paradigm for drug delivery. The company aims to dismantle barriers. These barriers often impede patient access. They complicate treatment regimens. Its technology makes medicine more personal. It makes it more manageable for individuals.
The rebrand to Terrestrial Bio reflects this broader ambition. "Terrestrial" signifies a grounded approach. It points to a surface-based technology. It also implies a global reach. The company seeks to impact patients worldwide. It connects innovative science with human needs.
Healthcare continues to evolve. Consumerization plays a growing role. Patients demand convenience. They expect ease of use. Terrestrial Bio addresses these demands directly. It offers a path to improved quality of life. It makes managing chronic conditions simpler.
This strategic investment positions Terrestrial Bio strongly. It enters a crucial phase of growth. The new manufacturing capabilities are vital. They ensure robust supply chains. They support global distribution plans. The company is set to advance next-generation therapies. It promises improved patient accessibility and unparalleled ease of use. This is the future of medicine, delivered directly to the skin.